Type 2 Diabetes Mellitus (T2DM)
Conditions
Keywords
Type 2 Diabetes Mellitus, T2DM, Fixed-dose combination, SGLT2 inhibitor, Thiazolidinedione, Dual therapy, Glycemic control, Insulin resistance, Randomized clinical trial, Phase III trial, Diabetes treatment, Oral antidiabetic drugs, Metformin adjunct therapy, HbA1c reduction, Cardiovascular risk factors, Renal protection, Diabetes complications, Monotherapy comparison, Drug combination efficacy, Diabetes management
Brief summary
This clinical trial is studying whether combining two commonly used diabetes medications into a single pill works better than taking them separately for people with type 2 diabetes who are already on metformin. Both medications work in different ways to lower blood sugar - one helps remove excess sugar through urine while the other helps the body use insulin better. The study has two main goals: To see if the combined pill controls blood sugar more effectively than either medication alone To check if combining them reduces common side effects like weight gain and swelling that can occur with one of the medications Participants will be randomly assigned to one of three groups: The new combination pill One of the standard diabetes medications alone The other standard diabetes medication alone All participants will take their assigned treatment daily and attend regular clinic visits for monitoring. Doctors will track blood sugar control, weight changes, and any side effects throughout the study period. This research could lead to a simpler treatment option that combines the benefits of both medications while potentially minimizing side effects. For people with diabetes who often need multiple medications, a combined pill might make treatment easier to manage while providing better blood sugar control.
Detailed description
This phase III clinical trial investigates a fixed-dose combination (FDC) of two established antidiabetic medications with complementary mechanisms of action: an SGLT2 inhibitor and a thiazolidinedione (TZD). The study aims to evaluate whether combining these medications in a single tablet provides superior glycemic control compared to either medication alone in patients with type 2 diabetes who are already on metformin therapy. The SGLT2 inhibitor component lowers blood glucose by increasing urinary glucose excretion, while the TZD component improves insulin sensitivity. Previous studies have shown that these drug classes may offer complementary benefits for metabolic control and cardiovascular risk reduction. However, the TZD component has been associated with side effects including fluid retention and weight gain in some patients. This trial will assess whether the combination can maintain the therapeutic benefits of both drugs while potentially reducing TZD-related adverse effects. The randomized, double-blind, double-dummy design compares three treatment arms: the FDC, SGLT2 inhibitor monotherapy, and TZD monotherapy. The primary endpoint is the change in HbA1c from baseline after 24 weeks of treatment. Secondary endpoints include measures of safety, tolerability, and additional metabolic parameters. Participants will undergo regular monitoring including blood tests, physical examinations, and safety assessments throughout the study period. The trial includes specific protocols for detecting and managing potential side effects, particularly those related to fluid retention. This study addresses an important clinical question regarding optimal treatment strategies for type 2 diabetes, particularly the potential advantages of fixed-dose combinations in simplifying treatment regimens while maintaining efficacy and safety. The results may provide evidence for a new therapeutic option that combines the established benefits of these two drug classes while potentially mitigating some limitations of monotherapy approaches.
Interventions
DRUGFixed-dose combination of SGLT2 inhibitor and thiazolidinedione
Oral fixed-dose combination tablet containing an SGLT2 inhibitor and a thiazolidinedione, administered once daily. Participants also receive matching placebos for both comparator drugs to maintain blinding. All participants continue background metformin therapy (≥1000mg/day).
DRUGControl Group 1 Intervention - SGLT2 inhibitor monotherapy
Oral tablet containing an SGLT2 inhibitor, administered once daily. Participants also receive matching placebos for both the fixed-dose combination and the thiazolidinedione comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). This represents standard monotherapy for comparison against the combination approach.
DRUGControl Group 2 Intervention - Thiazolidinedione monotherapy
Oral tablet containing a thiazolidinedione, administered once daily. Participants also receive matching placebos for both the fixed-dose combination and the SGLT2 inhibitor comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). This represents standard monotherapy for comparison against the combination approach.
DRUGBackground Therapy (All Groups) - Metformin
Extended-release metformin tablets (≥1000mg daily) continued as background therapy for all participants throughout the study duration.
Sponsors
Eurofarma Laboratorios S.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent form * Age ≥18 years * Diagnosis of type 2 diabetes (T2DM) * HbA1c 7.5-10% while on stable metformin monotherapy (≥1000 mg/day) for ≥12 weeks * ≥80% adherence to run-in medication
Exclusion criteria
* Type 1 diabetes or other specific diabetes types (e.g., monogenic, pancreatic, or drug-induced) * Severe hyperglycemia (≥270 mg/dL) or diabetic ketoacidosis in past 12 weeks * Hypersensitivity to study drugs or excipients * Pregnancy, lactation, or planning pregnancy * Severe diabetic complications (proliferative retinopathy, severe neuropathy) * Major cardiovascular events in past 12 weeks (e.g., myocardial infarction, heart failure NYHA III/IV) * Uncontrolled hypertension (SBP \>180 mmHg or DBP \>110 mmHg) * Moderate/severe renal impairment (eGFR \<45 mL/min/1.73m²) * Liver disease (cirrhosis, active hepatitis) * History of malignancy (except treated skin cancers) in past 5 years * Use of non-metformin antidiabetics or weight-loss drugs in past 12 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in glycated hemoglobin (HbA1c) from baseline to week 24 | From baseline to week 24 |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of participants achieving HbA1c <7.0% at week 24 | At week 24 |
| Change in fasting plasma glucose from baseline to week 24 | Baseline to week 24 |
| Incidence of peripheral edema over 24 weeks | Baseline to week 24 |
| Incidence of moderate/severe hypoglycemia (Level 2/3) over 24 weeks | Baseline to week 24 |
| Incidence of adverse events (AEs) over 24 weeks | Baseline to week 24 |
Other
| Measure | Time frame |
|---|---|
| Change in body weight from baseline to week 24 | Baseline to week 24 |
Countries
Brazil
Outcome results
None listed